Posted by Michael Wonder on 16 Oct 2023
Mundipharma and Cidara Therapeutics receive positive CHMP opinion for rezafungin for the treatment of invasive candidiasis in adults
13 October 2023 - The opinion was based on positive results from the pivotal ReSTORE Phase 3 clinical trial and supported by the STRIVE Phase 2 clinical trials and extensive nonclinical development program.
Mundipharma and Cidara Therapeutics today announced that the EMA's CHMP has adopted a positive opinion for rezafungin (rezafungin acetate) for the treatment of invasive candidiasis in adults.
